Levetiracetam in refractory pediatric epilepsy

James Wheless, Yu Tze Ng

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Levetiracetam, one of the newer-generation antiepilepsy drugs, is not currently approved for use in children. Given its favorable efficacy, pharmacokinetic, and, particularly, safety profile in adults, we felt that it may be a useful antiepilepsy drug for children with refractory epilepsy. We treated 39 patients (mean age 8.6 years) with open-label levetiracetam for up to 9 months. Seizure frequency, drug dosages, adverse events, and neurologic examinations were documented at baseline and routine follow-up visits. Levetiracetam, as add-on therapy, was effective in reducing seizure frequency in a variety of seizure types but was most effective for partial-onset seizures. Fourteen patients were discontinued for lack of efficacy or adverse events. Ten patients reported improvements in cognition or behavior. Levetiracetam was generally effective and well tolerated in this open-label study. Its apparent positive effects on cognition in some patients are encouraging. Large, well-controlled studies are needed to fully define levetiracetam’s potential in children with refractory epilepsy.

Original languageEnglish (US)
Pages (from-to)413-415
Number of pages3
JournalJournal of Child Neurology
Volume17
Issue number6
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

etiracetam
Epilepsy
Pediatrics
Seizures
Cognition
Neurologic Examination
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Pharmacokinetics
Safety

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Levetiracetam in refractory pediatric epilepsy. / Wheless, James; Ng, Yu Tze.

In: Journal of Child Neurology, Vol. 17, No. 6, 01.01.2002, p. 413-415.

Research output: Contribution to journalArticle

Wheless, James ; Ng, Yu Tze. / Levetiracetam in refractory pediatric epilepsy. In: Journal of Child Neurology. 2002 ; Vol. 17, No. 6. pp. 413-415.
@article{43804cd4bf6e4a899efcec8ad93dd2a7,
title = "Levetiracetam in refractory pediatric epilepsy",
abstract = "Levetiracetam, one of the newer-generation antiepilepsy drugs, is not currently approved for use in children. Given its favorable efficacy, pharmacokinetic, and, particularly, safety profile in adults, we felt that it may be a useful antiepilepsy drug for children with refractory epilepsy. We treated 39 patients (mean age 8.6 years) with open-label levetiracetam for up to 9 months. Seizure frequency, drug dosages, adverse events, and neurologic examinations were documented at baseline and routine follow-up visits. Levetiracetam, as add-on therapy, was effective in reducing seizure frequency in a variety of seizure types but was most effective for partial-onset seizures. Fourteen patients were discontinued for lack of efficacy or adverse events. Ten patients reported improvements in cognition or behavior. Levetiracetam was generally effective and well tolerated in this open-label study. Its apparent positive effects on cognition in some patients are encouraging. Large, well-controlled studies are needed to fully define levetiracetam’s potential in children with refractory epilepsy.",
author = "James Wheless and Ng, {Yu Tze}",
year = "2002",
month = "1",
day = "1",
doi = "10.1177/088307380201700603",
language = "English (US)",
volume = "17",
pages = "413--415",
journal = "Journal of Child Neurology",
issn = "0883-0738",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Levetiracetam in refractory pediatric epilepsy

AU - Wheless, James

AU - Ng, Yu Tze

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Levetiracetam, one of the newer-generation antiepilepsy drugs, is not currently approved for use in children. Given its favorable efficacy, pharmacokinetic, and, particularly, safety profile in adults, we felt that it may be a useful antiepilepsy drug for children with refractory epilepsy. We treated 39 patients (mean age 8.6 years) with open-label levetiracetam for up to 9 months. Seizure frequency, drug dosages, adverse events, and neurologic examinations were documented at baseline and routine follow-up visits. Levetiracetam, as add-on therapy, was effective in reducing seizure frequency in a variety of seizure types but was most effective for partial-onset seizures. Fourteen patients were discontinued for lack of efficacy or adverse events. Ten patients reported improvements in cognition or behavior. Levetiracetam was generally effective and well tolerated in this open-label study. Its apparent positive effects on cognition in some patients are encouraging. Large, well-controlled studies are needed to fully define levetiracetam’s potential in children with refractory epilepsy.

AB - Levetiracetam, one of the newer-generation antiepilepsy drugs, is not currently approved for use in children. Given its favorable efficacy, pharmacokinetic, and, particularly, safety profile in adults, we felt that it may be a useful antiepilepsy drug for children with refractory epilepsy. We treated 39 patients (mean age 8.6 years) with open-label levetiracetam for up to 9 months. Seizure frequency, drug dosages, adverse events, and neurologic examinations were documented at baseline and routine follow-up visits. Levetiracetam, as add-on therapy, was effective in reducing seizure frequency in a variety of seizure types but was most effective for partial-onset seizures. Fourteen patients were discontinued for lack of efficacy or adverse events. Ten patients reported improvements in cognition or behavior. Levetiracetam was generally effective and well tolerated in this open-label study. Its apparent positive effects on cognition in some patients are encouraging. Large, well-controlled studies are needed to fully define levetiracetam’s potential in children with refractory epilepsy.

UR - http://www.scopus.com/inward/record.url?scp=0036592712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036592712&partnerID=8YFLogxK

U2 - 10.1177/088307380201700603

DO - 10.1177/088307380201700603

M3 - Article

VL - 17

SP - 413

EP - 415

JO - Journal of Child Neurology

JF - Journal of Child Neurology

SN - 0883-0738

IS - 6

ER -